Indian pharma stocks surge to record levels on market momentum

Pharmaceutical stocks extended their winning streak on Friday as a wave of buying lifted companies across the sector to new peaks. Symbiotec Pharmalab, Windlas Biotech, Sai Life Sciences, Alembic Pharmaceuticals and Fermation Biotech led the charge, each recording gains ranging from 9 to 20 percent during the session.

The broad-based rally underscores growing investor appetite for India's pharmaceutical players, particularly mid-cap firms with exposure to domestic and international markets. Aurobindo Pharma, Divi's Laboratories and Glenmark Pharmaceuticals also reached new highs, signalling sustained momentum across the sector's major constituents.

The pharmaceutical industry has emerged as a key beneficiary of structural tailwinds, including India's position as a major supplier of generic medicines globally and rising domestic healthcare consumption. Analysts attribute recent strength to improving earnings expectations and positive sentiment around regulatory developments.

The sector's performance on Friday added to recent gains, reflecting what market participants view as a rotation toward defensive, earnings-stable stocks amid broader market volatility.